GZ 402674Alternative Names: GZ402674
Latest Information Update: 16 Jul 2016
At a glance
- Originator Sanofi
- Class Antineoplastics
- Mechanism of Action DNA topoisomerase I inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in Europe
- 26 Jul 2012 Phase-I clinical trials in Solid tumours in Europe (unspecified route)